{
  "success": true,
  "pagesUsed": [
    4,
    5,
    6,
    8,
    9,
    10,
    12,
    13,
    14,
    20,
    21,
    22,
    23,
    27,
    28,
    29,
    30,
    31,
    38,
    39,
    40,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "efanesoctocog alfa",
        "type": {
          "id": "d941408c-0703-49c8-b492-e043973a7e83",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "31c9b27e-b44b-4f50-9d1d-f8d938877382",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Recombinant coagulation factor VIII Fc-von Willebrand Factor XTEN Fusion Protein (BIVV001) for the treatment of severe hemophilia A.",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "FVIII product",
        "type": {
          "id": "a2f07118-c222-4a68-80b7-18d0edc9d499",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "a542c78f-f5c3-4bf7-a54f-be77fc2f52ed",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Previous treatment for hemophilia A with any recombinant and/or plasma-derived FVIII, or cryoprecipitate for at least 150 exposure days.",
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Emicizumab",
        "type": {
          "id": "74a984f7-60b6-4c94-9056-544882014c4c",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "a1c359f0-bec9-4f96-86b4-88144161b9b9",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prophylactic emicizumab therapy; must be washed out for 20 weeks prior to screening.",
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Acetylsalicylic acid (ASA)",
        "type": {
          "id": "b20325fc-82b1-4e7f-ad03-6b1061abf286",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "eec0536c-8ce3-42ec-a7d2-0fedd2b77f29",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited within 2 weeks prior to screening.",
        "administrationIds": [
          "admin_4"
        ]
      },
      {
        "id": "int_5",
        "name": "Non-steroidal anti-inflammatory drugs (NSAIDs)",
        "type": {
          "id": "f268f362-15a6-41db-a35c-f12dbf005807",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "7431c45e-01a7-4547-9476-59f7fb126dd0",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited above maximum dose specified in regional prescribing information within 2 weeks prior to screening.",
        "administrationIds": [
          "admin_5"
        ]
      },
      {
        "id": "int_6",
        "name": "Immunosuppressive drugs",
        "type": {
          "id": "4e8355b6-7080-4422-bf50-bf2dd33a19da",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "a804c5d4-b92c-4b64-b2fc-07b080a96d70",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Systemic treatment prohibited within 12 weeks prior to screening (except for HCV or HIV treatment)."
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "BIVV001",
        "administrableDoseForm": {
          "id": "5d03563b-ce29-4f96-b845-ac31d78673d3",
          "code": "C42970",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Powder",
          "standardCode": {
            "id": "b0723ad1-c99c-449c-9db5-b53529d345be",
            "code": "C42970",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Powder",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "94c02e8b-fc01-4394-8061-1fb497c6ed93",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "250, 500, 1000, 2000, 3000, and 4000 IU per vial",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Sanofi"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Arm A Prophylaxis",
        "instanceType": "Administration",
        "dose": "50 IU/kg",
        "doseFrequency": "once weekly",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "52 weeks"
      },
      {
        "id": "admin_2",
        "name": "Arm B On-Demand",
        "instanceType": "Administration",
        "dose": "50 IU/kg",
        "doseFrequency": "as needed for bleeding episodes",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "26 weeks"
      },
      {
        "id": "admin_3",
        "name": "Arm B Prophylaxis (Switch)",
        "instanceType": "Administration",
        "dose": "50 IU/kg",
        "doseFrequency": "once weekly",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "26 weeks"
      },
      {
        "id": "admin_4",
        "name": "Bleeding Episode Treatment",
        "instanceType": "Administration",
        "dose": "50 IU/kg (initial), 30 or 50 IU/kg (follow-up)",
        "doseFrequency": "every 2 to 3 days if needed",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Until bleeding is controlled"
      },
      {
        "id": "admin_5",
        "name": "Surgical Dosing (Minor/Major)",
        "instanceType": "Administration",
        "dose": "50 IU/kg (loading dose)",
        "doseFrequency": "Repeated doses of 30 or 50 IU/kg as needed",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Perioperative period"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "efanesoctocog alfa",
        "instanceType": "Substance",
        "description": "Recombinant coagulation factor VIII Fc-von Willebrand Factor XTEN Fusion Protein"
      }
    ],
    "medicalDevices": [
      {
        "id": "dev_1",
        "name": "electronic Patient Diary (ePD)",
        "instanceType": "MedicalDevice",
        "manufacturer": "Not specified"
      },
      {
        "id": "dev_2",
        "name": "ActiGraph Activity Monitor",
        "instanceType": "MedicalDevice",
        "manufacturer": "ActiGraph"
      }
    ],
    "summary": {
      "interventionCount": 6,
      "productCount": 1,
      "deviceCount": 2
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "efanesoctocog alfa",
        "role": "Investigational Product",
        "description": "Recombinant coagulation factor VIII Fc-von Willebrand Factor XTEN Fusion Protein (BIVV001) for the treatment of severe hemophilia A."
      },
      {
        "name": "FVIII product",
        "role": "Prior Medication",
        "description": "Previous treatment for hemophilia A with any recombinant and/or plasma-derived FVIII, or cryoprecipitate for at least 150 exposure days."
      },
      {
        "name": "Emicizumab",
        "role": "Prior Medication",
        "description": "Prophylactic emicizumab therapy; must be washed out for 20 weeks prior to screening."
      },
      {
        "name": "Acetylsalicylic acid (ASA)",
        "role": "Concomitant Medication",
        "description": "Prohibited within 2 weeks prior to screening."
      },
      {
        "name": "Non-steroidal anti-inflammatory drugs (NSAIDs)",
        "role": "Concomitant Medication",
        "description": "Prohibited above maximum dose specified in regional prescribing information within 2 weeks prior to screening."
      },
      {
        "name": "Immunosuppressive drugs",
        "role": "Concomitant Medication",
        "description": "Systemic treatment prohibited within 12 weeks prior to screening (except for HCV or HIV treatment)."
      }
    ],
    "products": [
      {
        "name": "BIVV001",
        "doseForm": "Lyophilized powder in a sterile vial",
        "strength": "250, 500, 1000, 2000, 3000, and 4000 IU per vial",
        "manufacturer": "Sanofi"
      }
    ],
    "substances": [
      {
        "name": "efanesoctocog alfa",
        "description": "Recombinant coagulation factor VIII Fc-von Willebrand Factor XTEN Fusion Protein"
      }
    ],
    "administrations": [
      {
        "name": "Arm A Prophylaxis",
        "dose": "50 IU/kg",
        "frequency": "once weekly",
        "route": "Intravenous",
        "duration": "52 weeks"
      },
      {
        "name": "Arm B On-Demand",
        "dose": "50 IU/kg",
        "frequency": "as needed for bleeding episodes",
        "route": "Intravenous",
        "duration": "26 weeks"
      },
      {
        "name": "Arm B Prophylaxis (Switch)",
        "dose": "50 IU/kg",
        "frequency": "once weekly",
        "route": "Intravenous",
        "duration": "26 weeks"
      },
      {
        "name": "Bleeding Episode Treatment",
        "dose": "50 IU/kg (initial), 30 or 50 IU/kg (follow-up)",
        "frequency": "every 2 to 3 days if needed",
        "route": "Intravenous",
        "duration": "Until bleeding is controlled"
      },
      {
        "name": "Surgical Dosing (Minor/Major)",
        "dose": "50 IU/kg (loading dose)",
        "frequency": "Repeated doses of 30 or 50 IU/kg as needed",
        "route": "Intravenous",
        "duration": "Perioperative period"
      }
    ],
    "devices": [
      {
        "name": "electronic Patient Diary (ePD)",
        "manufacturer": "Not specified",
        "purpose": "To record bleeding episodes and treatment administration"
      },
      {
        "name": "ActiGraph Activity Monitor",
        "manufacturer": "ActiGraph",
        "purpose": "Triaxial medical grade accelerometer for physical activity monitoring"
      }
    ]
  }
}